TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24448756

Group type: EXPERIMENTAL
Intervention: Aranesp (Q weekly or Q 2 weeks)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Eprex (Q TIW or BIW)
Number of subjects: 139
Study: 23090813

Group type: EXPERIMENTAL
Intervention: 20 mg Methylphenidate (MPH)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 20712264

Group type: EXPERIMENTAL
Intervention: myo-inositol plus folic acid plus melatonin (group A)
Number of subjects: 65

Group type: COMPARATOR
Intervention: myo-inositol plus folic acid (group B)
Number of subjects: 65
Study: 18408527

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for psychotic depression
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Cumulative olanzapine dose
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 12-week trial completers
Number of subjects: 118
Study: 15842259

Group type: EXPERIMENTAL
Intervention: Open flap debridement (OFD) with PLA/PGA copolymer graft
Number of subjects: 32

Group type: COMPARATOR
Intervention: Open flap debridement (OFD) alone
Number of subjects: 32
Study: 12455799

Group type: EXPERIMENTAL
Intervention: Conventional peritoneal cytologic evaluation
Number of subjects: 108
Study: 10513763

Group type: EXPERIMENTAL
Intervention: Closed-ended questionnaire format
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Open-ended questionnaire format
Number of subjects: 1007
Study: 9111711

Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention
Number of subjects: 33

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 33
Study: 1749203

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg b.i.d.)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg b.i.d.)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination therapy (atenolol and nifedipine)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 27
Study: 6810863

Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate (SCG)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination of SCG and theophylline
Number of subjects: 26

Group type: COMPARATOR
Intervention: Oral theophylline
Number of subjects: 26
Study: 31349978

Group type: EXPERIMENTAL
Intervention: Intravenous Dodecafluoropentane emulsion (DDFPe)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose DDFPe
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28324038

Group type: EXPERIMENTAL
Intervention: Exenatide plus pioglitazone (combination therapy)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Basal plus prandial insulin (insulin therapy)
Number of subjects: 101
Study: 25400263

Group type: EXPERIMENTAL
Intervention: Running suture technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard interrupted suture technique
Number of subjects: 60
Study: 24792107

Group type: EXPERIMENTAL
Intervention: IntraLASE FS60 laser (IL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: WaveLight FS200 laser (FS)
Number of subjects: 40
Study: 21594619

Group type: EXPERIMENTAL
Intervention: Selumetinib (100 mg oral twice daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Capecitabine (1,250 mg/m² oral twice daily)
Number of subjects: 70
Study: 19349375

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (3 doses of 250 mg/kg per dose, 1 mL/kg per dose, 24 hours apart)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline infusion (3 doses of 1 mL/kg per dose, 24 hours apart)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 40
Study: 17224418

Group type: EXPERIMENTAL
Intervention: Active therapy (Pm ON)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo therapy (Pm OFF)
Number of subjects: 710
Study: 14684561

Group type: EXPERIMENTAL
Intervention: rhDNase (2.5 mg/day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: No rhDNase (control group)
Number of subjects: 105
Study: 12162793

Group type: EXPERIMENTAL
Intervention: Desloratadine 5-20 mg
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Desloratadine 5, 7.5, and 20 mg
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg QD
Number of subjects: 1026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1026
Study: 9839823

Group type: EXPERIMENTAL
Intervention: bupivacaine 150 mg + morphine 4 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bupivacaine 150 mg + morphine 4 mg + methylprednisolone 40 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: saline
Number of subjects: 60
Study: 7666668

Group type: EXPERIMENTAL
Intervention: MFC + continuous oral 5-FU (Group A)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: MFC + continuous oral UFT (Group B)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: MF + UFT (Group C)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: MFC + continuous oral 5-FU (Group A) at CAD
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: MFC + continuous oral UFT (Group B) at CAD
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: MF + UFT (Group C) at CAD
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: MFC + continuous oral 5-FU (Group A) at CIH
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: MF + UFT (Group C) at ACC
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: MFC + continuous oral UFT (Group B) at NCC
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Survival rate of patients with S2 (serosal exposure), 8 cm < and N0-1 cancer at CIH
Number of subjects: 466
Study: 3392363

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate aerosol (GA) 240 micrograms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate aerosol (GA) 480 micrograms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate aerosol (GA) 960 micrograms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31821993

Group type: EXPERIMENTAL
Intervention: BFR-LOW (40% of arterial occlusion pressure)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: PRACTICAL-LOW (30% of 1-RM)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: PRACTICAL-HIGH (elastic knee wraps stretched to 85% of thigh circumference)
Number of subjects: 9

Group type: COMPARATOR
Intervention: HL (70% 1-RM)
Number of subjects: 9
Study: 30608570

Group type: EXPERIMENTAL
Intervention: Brief alcohol interventions
Number of subjects: 836

Group type: COMPARATOR
Intervention: No/Low blackouts (n = 248; 29.7%)
Number of subjects: 836

Group type: COMPARATOR
Intervention: High blackouts (n = 159; 19.0%)
Number of subjects: 836

Group type: COMPARATOR
Intervention: Moderate blackouts (n = 337; 40.3%)
Number of subjects: 836
Study: 28500416

Group type: EXPERIMENTAL
Intervention: High GI breakfast followed by 2 min activity breaks every 20 min (HGI-ACT)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low GI breakfast followed by 2 min activity breaks every 20 min (LGI-ACT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High GI breakfast followed by uninterrupted sitting (HGI-SIT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low GI breakfast followed by uninterrupted sitting (LGI-SIT)
Number of subjects: 14
Study: 25559495

Group type: EXPERIMENTAL
Intervention: Multitiered oral health educational program for care staff
Number of subjects: 76

Group type: COMPARATOR
Intervention: No training for care staff (Control)
Number of subjects: 76
Study: 23242583

Group type: EXPERIMENTAL
Intervention: Omentum-preserving gastrectomy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Complete removal of the omentum
Number of subjects: 250
Study: 17098159

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 0
Study: 12663595

Group type: EXPERIMENTAL
Intervention: Exercise consultation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 10367608

Group type: EXPERIMENTAL
Intervention: Testosterone (daytime)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Testosterone (nighttime)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Testosterone (24-hour mean)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LH pulse frequency
Number of subjects: 15
Study: 8665335

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (10‐30 mg four times a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (four times a day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate cessation
Number of subjects: 12
Study: 2005708

Group type: EXPERIMENTAL
Intervention: 20 micrograms desmopressin spray
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 20, 30, and 40 micrograms desmopressin
Number of subjects: 52
Study: 6364441

Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg loading dose followed by 5.6 mg/h continuous infusion from midnight until 10 am)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31318492

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (PA)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Steps per day
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Energy intake (EI)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Fat intake
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Delayed sleep timing midpoint
Number of subjects: 227
Study: 27927048

Group type: EXPERIMENTAL
Intervention: BTDS 10 mcg/h
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: BTDS 40 mcg/h
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: BTDS 80 mcg/h
Number of subjects: 110

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Naltrexone with BTDS
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 25210019

Group type: EXPERIMENTAL
Intervention: Targeted albendazole therapy (n = 467)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Nontargeted albendazole therapy (n = 513)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Albendazole therapy (both targeted and nontargeted)
Number of subjects: 980
Study: 23471702

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of amlodipine, telmisartan, and hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual marketed products (reference)
Number of subjects: 0
Study: 21315132

Group type: EXPERIMENTAL
Intervention: Fixed partial dentures
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Removable partial dentures
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Complete dentures
Number of subjects: 500
Study: 20090396

Group type: EXPERIMENTAL
Intervention: MM+CPB
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: MM+TS
Number of subjects: 65

Group type: COMPARATOR
Intervention: MM
Number of subjects: 65
Study: 17923069

Group type: EXPERIMENTAL
Intervention: Clinical score assessment
Number of subjects: 110
Study: 15477698

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Agility training
Number of subjects: 98

Group type: COMPARATOR
Intervention: Stretching (sham) exercises
Number of subjects: 98
Study: 11354573

Group type: EXPERIMENTAL
Intervention: Aprotinin (280 mg in pump prime)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 9112303

Group type: EXPERIMENTAL
Intervention: Early mobilization (group A)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Sit up and take 20 deep breaths on 10 occasions daily (group B)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Sit up and blow bubbles in a bottle containing 10 cm water through a plastic tube 20 times on 10 occasions daily (group C)
Number of subjects: 145
Study: 8200556

Group type: EXPERIMENTAL
Intervention: ICS 205-930 (tropisetron)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3322828

Group type: EXPERIMENTAL
Intervention: Digoxin marker in capsules of gemfibrozil (4.4 micrograms twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digoxin marker in capsules of placebo (4.4 micrograms twice a day)
Number of subjects: 0
Study: 31537375

Group type: EXPERIMENTAL
Intervention: Dilute betadine (0.02% solution) added to sterile water (SW) splash basin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard sterile water (SW) splash basin
Number of subjects: 104
Study: 29112090

Group type: EXPERIMENTAL
Intervention: Clear liquid diet
Number of subjects: 184

Group type: COMPARATOR
Intervention: Low-fibre diet
Number of subjects: 184
Study: 28801440

Group type: COMPARATOR
Intervention: Not applicable (baseline study, no intervention implemented)
Number of subjects: 372
Study: 24758736

Group type: EXPERIMENTAL
Intervention: Baclofen 40 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24270300

Group type: EXPERIMENTAL
Intervention: Job-specific WHS
Number of subjects: 176

Group type: COMPARATOR
Intervention: Generic WHS (Control)
Number of subjects: 176
Study: 21575102

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg·kg(‐1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg·kg(‐1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 μg·kg(‐1)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (acetaminophen as needed)
Number of subjects: 160
Study: 18470742

Group type: EXPERIMENTAL
Intervention: Multiple channel exposure therapy (M-CET)
Number of subjects: 0
Study: 16782927

Group type: EXPERIMENTAL
Intervention: Carboplatin and cisplatin (CC)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Cisplatin + fluorouracil + vincristine (C5V)
Number of subjects: 109
Study: 12727673

Group type: EXPERIMENTAL
Intervention: Reported family history of cancer in males
Number of subjects: 150000

Group type: EXPERIMENTAL
Intervention: Reported family history of cancer in females
Number of subjects: 150000

Group type: EXPERIMENTAL
Intervention: Reported family history of cancer by gender
Number of subjects: 150000

Group type: EXPERIMENTAL
Intervention: Reported family history of cancer by ethnicity
Number of subjects: 150000

Group type: EXPERIMENTAL
Intervention: Reported family history of cancer by age
Number of subjects: 150000

Group type: EXPERIMENTAL
Intervention: Commonly reported cancers in families
Number of subjects: 150000

Group type: EXPERIMENTAL
Intervention: Reported cancer rates to expected cancer rates
Number of subjects: 150000

Group type: EXPERIMENTAL
Intervention: Reported:expected ratios for specific cancers
Number of subjects: 150000
Study: 10739358

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg i.v. every 3 weeks for a maximum of six cycles
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg i.v. every 3 weeks for a maximum of six cycles
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pamidronate treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Terminal care in hospital (last 3 months before death)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Average monthly direct costs during treatment phase
Number of subjects: 70

Group type: COMPARATOR
Intervention: Average monthly direct costs during follow-up
Number of subjects: 70

Group type: COMPARATOR
Intervention: In-patient costs
Number of subjects: 70
Study: 9176830

Group type: EXPERIMENTAL
Intervention: 1.25 g/day DHA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5 g/day DHA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (vegetable oil)
Number of subjects: 0
Study: 1412606

Group type: EXPERIMENTAL
Intervention: Single oral dose of 200 mg of labetalol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single intravenous dose of 0.5 mg/kg of labetalol
Number of subjects: 16
Study: 3926731

Group type: EXPERIMENTAL
Intervention: 1 litre of 20 per cent Intralipid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 12
Study: 30861510

Group type: EXPERIMENTAL
Intervention: Vaginal suppositories containing low‐molecular‐weight hyaluronic acid (HA) from day 1 of radiotherapy for 5 weeks.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 180
Study: 29956364

Group type: EXPERIMENTAL
Intervention: Chocolate cookies (cookie group)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no cookies)
Number of subjects: 118
Study: 26972955

Group type: EXPERIMENTAL
Intervention: Diet therapy plus pravastatin
Number of subjects: 3170

Group type: COMPARATOR
Intervention: Diet therapy alone
Number of subjects: 3170
Study: 25227834

Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM) intervention
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Integration of HBM and Theory of Planned Behavior (TPB) constructs intervention
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study: 22490761

Group type: EXPERIMENTAL
Intervention: Web-based tailored lifestyle advice and personal counselling
Number of subjects: 340

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 340
Study: 20942575

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (combination of antioxidants extracted from fruit, berries, and vegetables) for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 40
Study: 17541115

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15653210

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 12122521

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham physiotherapy
Number of subjects: 60
Study: 10357412

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with monitoring using [technetium 99m]-sestamibi (MIBI) scintimammography
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pretherapy imaging using [technetium 99m]-sestamibi (MIBI) scintimammography
Number of subjects: 32
Study: 7497759

Group type: EXPERIMENTAL
Intervention: Normothermic CPB (n = 19, rectal temperature: 35.9 ± 0.1 degrees C)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Hypothermic CPB (n = 19, rectal temperature: 29.2 ± 0.5 degrees C)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (Normothermic and Hypothermic)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Peak plasma elastase levels
Number of subjects: 38
Study: 2149508

Group type: EXPERIMENTAL
Intervention: Goserelin (Zoladex) 3.6 mg depot preparation combined with flutamide (Eulexin) 250 mg t.i.d.
Number of subjects: 327

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 327
Study: 6997516

Group type: EXPERIMENTAL
Intervention: Single 2-g dose of metronidazole
Number of subjects: 176

Group type: COMPARATOR
Intervention: Seven-day regimen of metronidazole (250 mg three times daily)
Number of subjects: 176
Study: 30356229

Group type: EXPERIMENTAL
Intervention: Virtual reality‐based training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 54
Study: 26164807

Group type: EXPERIMENTAL
Intervention: Obese group (BMI ≥ 30 kg/m²)
Number of subjects: 771

Group type: COMPARATOR
Intervention: Nonobese group (BMI 23.4 ± 2.6 kg/m²)
Number of subjects: 771
Study: 24173773

Group type: EXPERIMENTAL
Intervention: rhIGF-I/rhIGFBP-3 complex
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 22126349

Group type: EXPERIMENTAL
Intervention: Fluoride chewing gum (FCG: 50 μg fluoride)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 45
Study: 18174269

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1.2 g/day for 2 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Zinc (Zn) 60 mg/day for 1 day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 17023703

Group type: EXPERIMENTAL
Intervention: Soy protein with native phytate (40 g/d)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Soy protein with native isoflavones
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Baseline BMI
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: HDL cholesterol
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: LDL cholesterol and BMI
Number of subjects: 55
Study: 12389880

Group type: EXPERIMENTAL
Intervention: Telephone follow-up (48-72 hours after discharge)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no telephone follow-up)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Follow-up group (telephone follow-up)
Number of subjects: 150
Study: 9822499

Group type: EXPERIMENTAL
Intervention: Daily aspirin (60 mg)
Number of subjects: 2539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2539
Study: 7859450

Group type: EXPERIMENTAL
Intervention: Multiple clips for tubal occlusion
Number of subjects: 510

Group type: COMPARATOR
Intervention: Single clip for tubal occlusion
Number of subjects: 510
Study: 2698360

Group type: EXPERIMENTAL
Intervention: Trabeculectomy at diagnosis followed by supplementary medical therapy if necessary
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional management of medical therapy followed by trabeculectomy in unsuccessful cases
Number of subjects: 116
Study: 4876730

Group type: EXPERIMENTAL
Intervention: Therapeutic trial treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Earlier trial treatment in Morocco
Number of subjects: 0
Study: 395128

Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31369613

Group type: EXPERIMENTAL
Intervention: Motor control (low‐dose exercise) and manual therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: General strength and conditioning training (moderate‐dose exercise)
Number of subjects: 40
Study: 29190852

Group type: COMPARATOR
Intervention: Traditional Circuit Resistance Training (TCRT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Instability Circuit Resistance Training (ICRT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 44